Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg. Gilead had the right to ...

Weeks after settling a five-year patent dispute with the U.S. government for an undisclosed sum, California's Gilead Sciences revealed that it has set aside $200 million for a potential resolution ...

In the latest market close, Gilead Sciences (GILD) reached $115.99, with a +1.47% movement compared to the previous day. This move outpaced the S&P 500's daily loss of 1.76%. Meanwhile ...

Deutsche Bank upgraded Gilead Sciences (NASDAQ:GILD) on Tuesday, citing the antiviral developer’s HIV treatment franchise, and downgraded Merck (NYSE:MRK), citing the cancer drugmaker’s ...

Gilead (GILD) announced that the FDA has accepted its new drug application submissions for lenacapavir, the company’s twice-yearly injectable HIV-1 capsid inhibitor-for the prevention of HIV as ...

16 analysts have shared their evaluations of Gilead Sciences GILD during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a condensed view of ...

A 2.5-square-foot plot of grass in Japan has snatched the Guinness World Record for the smallest ever park. The micro-park — barely larger than two New York Post front pages — is in Nagaizumi ...

Kennet Brysting, president of Gilead Sciences Japan, mentioned an intriguing possibility during an interview in Tokyo late last year. “I do believe that Japan could be one of the first countries ...

The Friends of Stockley Park have been working hard to transform the once-neglected green space in Appley Bridge. The latest addition is a book exchange for use by the community, where people can ...

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against other Renaissance Technologies portfolio’s top stock picks. The American quant hedge ...

Looking at the universe of stocks we cover at Dividend Channel, in trading on Friday, shares of Gilead Sciences Inc (Symbol: GILD) were yielding above the 3% mark based on its quarterly dividend ...